Promising Advances in MDS, AML, and Bleeding Disorders to Headline ASH 2025
ORLANDO, FL – New analyses of venetoclax in high-risk myelodysplastic syndromes (MDS), evolving treatment strategies for acute myeloid leukemia (AML) progressing from MDS, and advancements in perioperative bleeding management for pediatric von Willebrand disease are poised to be key discussion points at the 2025 American Society of Hematology (ASH) annual meeting. These developments signal a period of rapid innovation across multiple hematologic malignancies and bleeding disorders, potentially reshaping clinical practice.
While a recent trial evaluating venetoclax in high-risk MDS did not meet its primary endpoint, emerging data suggest specific patient subgroups may still experience significant benefit. This focus on identifying responsive populations is a central theme, alongside progress in targeted therapies for AML patients who have progressed from inadequately treated MDS.Simultaneously, research is concentrating on improving access and delivery methods for therapies addressing rare bleeding disorders, especially for women and adolescent females.
Ivo Carre, PhD, a senior business analyst at lifescience Dynamics, highlighted the importance of the upcoming subgroup analyses from the venetoclax trial. These insights are expected to refine future treatment strategies and enable more personalized approaches for patients with high-risk disease. The continued innovation in AML treatment, particularly with targeted therapies, is also a critical area of focus.
Shayla Bergmann, MD, a clinical professor in pediatric hematology at the Medical University of South Carolina, discussed a study focused on the perioperative management of bleeding in pediatric patients with severe von Willebrand (VWF) disease using recombinant VWF. Priorities include optimizing prophylactic treatment and expanding access to more convenient therapies, such as subcutaneous formulations, to reduce reliance on intravenous delivery. A key area of unmet need is addressing the unique challenges faced by women and adolescent females with bleeding disorders related to menstruation, fertility, pregnancy, and childbirth.
These collective advancements underscore a dynamic landscape in hematology, setting the stage for impactful discussions and potentially practice-changing insights at ASH 2025.
